title: Adverse effects of incretin therapy for type 2 diabetes.
authors.forename: Eric
authors.initials: E
authors.lastname: Grouzmann
authors.forename: Michel
authors.initials: M
authors.lastname: Monod
authors.forename: Basil N
authors.initials: BN
authors.lastname: Landis
authors.forename: Jean-Silvain
authors.initials: JS
authors.lastname: Lacroix
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007249:Inflammation; D009304:Nasopharyngitis; D013373:Substance P
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D013373:Substance P; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4